Table 2.

Enthesitis at week 24 (LOCF) and weeks 52, 104 and 156 (as observed)*

MASES†	Week 24			Week 52		Week 104		Week 156
	Placebo (n=302)	Apremilast		Apremilast		Apremilast		Apremilast
		30 mg two times per day (n=315)	20 mg two times per day (n=298)	30 mg two times per day (n=377)	20 mg two times per day (n=326)	30 mg two times per day (n=302)	20 mg two times per day (n=261)	30 mg two times per day (n=278)	20 mg two times per day (n=227)
Baseline, mean	4.8	4.4	4.6	4.4	4.5	4.3	4.6	4.2	4.4
Mean change from baseline	−0.9	−1.3‡	−1.2	−2.0	−2.2	−2.6	−2.6	−2.7	−2.8
Mean per cent change from baseline	−7.0	−23.6‡	−19.3	−43.5	−42.2	−57.5	−55.2	−65.2	−57.6
Median per cent change from baseline§	−21.1	−50.0‡	−40.0	−66.7	−66.7	−85.7	−100.0	−100.0	−100.0
Score of 0¶, n/m (%)	70/311 (22.5)	90/327 (27.5)	84/307 (27.4)	142/377 (37.7)	134/326 (41.1)	147/302 (48.7)	135/261 (51.7)	153/278 (55.0)	125/227 (55.1)

*The n at week 24 represents patients with a baseline value >0 and ≥1 postbaseline value at or before week 24. Data as observed for weeks 52, 104 and 156; the n represents the number of patients taking apremilast, regardless of when treatment started (baseline, week 16 or week 24), with a baseline value >0 and a value at the specific visit.

†MASES ranges from 0 to 13, with 0 indicating no pain at any assessed entheses and 13 indicating pain at all assessed entheses.

‡P<0.05 vs placebo.

§The per cent change noted occurred in >50% of patients.

¶Patients who did not have sufficient data (observed or imputed) for a definitive determination of response status at week 24 are counted as non-responders.

LOCF, last observation carried forward; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score.